偶尔发现的儿童凝血异常的重要性
Gökçen Meral1, Ayça Koca Yozgat2, Vildan Çulha2
1Department of Pediatrics, Ankara City Hospital, Cankaya, Turkey.
概括
轻度凝血因子缺陷比预期的更常见,有偶尔延长的前血栓时间 (PT) 或激活的部分血栓形成时间 (aPTT). 这些轻微的缺陷往往没有出血史,其临床意义尚不清楚.
科学领域:
- 儿童血液学
- 血液静止和血栓形成
- 临床凝血
背景情况:
- 一个彻底的病史和体检通常会发现大多数出血障碍.
- 这项研究研究了儿科患者的血静性疾病,这些患者偶尔会出现延长的前血时间 (PT) 或激活的部分血栓形成时间 (aPTT).
研究的目的:
- 确定儿科患者中偶尔PT/aPTT延长的血静性疾病的发生率和类型.
- 评估该群体中轻度因子缺乏症的临床意义.
主要方法:
- 没有先前的血液病的儿科患者被纳入.
- 分析了凝血因子的活性. 对异常混合的患者进行了抗脂抗体和狼抗凝试验.
主要成果:
- 在103名患者中,有50名患者在重新测试时出现了持续的PT/ aPTT异常.
- 在总队列中,有30%的患者患有凝血病 (60%的患者患有持续性异常).
- 最常见的缺陷包括XII因子 (5.8%),XI因子 (4.8%) 和VII因子 (2.9%).
结论:
- 在偶尔PT/ APTT延长的儿童中,轻微的凝血因子缺陷比预期的更为普遍.
- 这些轻微的缺陷可能发生在没有出血史的患者中.
- 这些轻度因子缺陷的临床意义和影响往往是未知的.
相关概念视频
Disorders of Hemostasis
1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K
Coagulation
7.4K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
7.4K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889
Extrinsic and Intrinsic Pathways of Hemostasis
9.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.2K
Introduction to Hemostasis
8.9K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
8.9K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K


